Capmatinib: First Approval

2020/06/18 by Sohita Dhillon · 25 citations
Medicine · Biochemistry, Genetics and Molecular Biology · #Lung Cancer Treatments and Mutations #Pancreatic and Hepatic Oncology Research #Cancer Genomics and Diagnostics

paper · doi:10.1007/s40265-020-01347-3

Cited by

• MET exon 14 skipping mutation, amplification and overexpression in pulmonary sarcomatoid carcinoma: A multi-center study. [europepmc]
• Spectrum of Mesenchymal-Epithelial Transition Aberrations and Potential Clinical Implications: Insights From Integrative Pancancer Analysis. [europepmc]
• Multiplex RNA-based detection of clinically relevant MET alterations in advanced non-small cell lung cancer. [europepmc]
• Current and future treatment options for MET exon 14 skipping alterations in non-small cell lung cancer. [europepmc]
• Novel Receptor Tyrosine Kinase Pathway Inhibitors for Targeted Radionuclide Therapy of Glioblastoma. [europepmc]
• Innovations and Patent Trends in the Development of USFDA Approved Protein Kinase Inhibitors in the Last Two Decades. [europepmc]
• Cancer Therapy Guided by Mutation Tests: Current Status and Perspectives. [europepmc]
• Macrocyclic Inhibitors of HGF-Activating Serine Proteases Overcome Resistance to Receptor Tyrosine Kinase Inhibitors and Block Lung Cancer Progression. [europepmc]
• FDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from Early 2011 to the End of 2021. [europepmc]
• Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation. [europepmc]
• Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program. [europepmc]
• Management of Peripheral Edema in Patients with MET Exon 14-Mutated Non-small Cell Lung Cancer Treated with Small Molecule MET Inhibitors. [europepmc]
• Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. [europepmc]
• Multi-target direct-acting SARS-CoV-2 antivirals against the nucleotide-binding pockets of virus-specific proteins. [europepmc]
• Study of the anticancer effect of new quinazolinone hydrazine derivatives as receptor tyrosine kinase inhibitors. [europepmc]
• Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer. [europepmc]
• Approved Small-Molecule ATP-Competitive Kinases Drugs Containing Indole/Azaindole/Oxindole Scaffolds: R&D and Binding Patterns Profiling. [europepmc]
• Clinical Relevance of Targeted Therapy and Immune-Checkpoint Inhibition in Lung Cancer. [europepmc]
• c-Met Mediated Cytokine Network Promotes Brain Metastasis of Breast Cancer by Remodeling Neutrophil Activities. [europepmc]
• The Development and Role of Capmatinib in the Treatment of MET-Dysregulated Non-Small Cell Lung Cancer-A Narrative Review. [europepmc]
• Resistance of Lung Cancer to EGFR-Specific Kinase Inhibitors: Activation of Bypass Pathways and Endogenous Mutators. [europepmc]
• Targeting MET in NSCLC: An Ever-Expanding Territory. [europepmc]
• A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib. [europepmc]
• Tumor biomarkers for diagnosis, prognosis and targeted therapy. [europepmc]
• Kinase Inhibitors and Kinase-Targeted Cancer Therapies: Recent Advances and Future Perspectives. [europepmc]